1421-23-4Relevant academic research and scientific papers
BIGUANIDE COMPOUND AND USE THEREOF
-
Paragraph 0246; 0247; 0278; 0279, (2017/10/07)
The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.
Expeditious synthesis and biological evaluation of novel 2,N 6-disubstituted 1,2-dihydro-1,3,5-triazine-4,6-diamines as potential antimalarials
Gravestock, David,Rousseau, Amanda L.,Lourens, Anna C.U.,Moleele, Simon S.,Van Zyl, Robyn L.,Steenkamp, Paul A.
experimental part, p. 2022 - 2030 (2011/06/21)
A small set of novel 2,N6-disubstituted 1,2-dihydro-1,3,5- triazine-4,6-diamines was prepared possessing a flexible tether between the exocyclic nitrogen bonded to C-6 of the 1,2-dihydro-1,3,5-triazine-4,6-diamine heterocycle and the distal ary
Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers
Ma, Xiang,Poon, Thong-Yuen,Wong, Peter Tsun Hon,Chui, Wai-Keung
supporting information; experimental part, p. 5644 - 5647 (2010/04/26)
Neuronal sodium channels blockers interfere with ion flux and have been used for managing neuropathic pain, epilepsy, and cerebral ischemic disorders. In the current study, four groups of 2,4-diamino-1,3,5-triazine derivatives were synthesized and investigated for their neuronal sodium channels binding activity. 5-Aryl-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamines (4a-4j) were found to have the best neuronal sodium binding activity among the four groups of triazines evaluated. Derivatives 4a-4j blocked the sodium channels with IC50 values ranged from 4.0 to 14.7 μM. The result from this study showed that analogues of 2,4-diamino-1,3,5-triazines could be used as leads for the discovery of neuronal sodium channels blockers for managing central nervous system related disorders.
Synthesis, crystal structure and biological properties of a new series of lipophilic s-triazines, dihydrofolate reductase inhibitors
Tsitsa,Antoniadou-Vyza,Hamodrakas,Eliopoulos,Tsantili-Kakoulidou,Lada-Hytiroglou,Roussakis,Chinou,Hempel,Camerman,Ottensmeyer,Vanden Berghe
, p. 149 - 158 (2007/10/02)
A number of adamantyl-group-bearing diamino-s-triazines were synthesized as potential dihydrofolate reductase (DHFR) inhibitors and their pharmacological properties were tested. The crystal structures of certain compounds were determined by X-ray crystallography. With the aid of computer graphics, model structures of the L1210 mouse DHFR-ligand ternary complex were constructed. The binding affinities of the compounds to DHFR were determined experimentally. Compounds mono-substituted at the nitrogen of the amine group appear to be slightly better inhibitors. Weak activity was also enhanced by the presence of a methylene bridge between the adamantyl group and the s-triazine ring. The majority of the compounds was shown to have weak activity against P388 and KB cell lines in vitro; some compounds showed weak anti-bacterial activity and no anti-viral activity was detected.
